Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

Amit Bahl; Andrew Chilelli; Rita Faria; Nigel Rozario; Robert Snijder; Sari Stark; Axel S. Merseburger

doi:10.1007/s00345-025-06100-7

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

Amit Bahl^*, Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder, Sari Stark, Axel S. Merseburger

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Urologie

Originalsprache	Englisch
Aufsatznummer	5
Zeitschrift	World Journal of Urology
Jahrgang	44
Ausgabenummer	1
ISSN	0724-4983
DOIs	https://doi.org/10.1007/s00345-025-06100-7
Publikationsstatus	Veröffentlicht - 01.2026

Fördermittel

This study which the letter describes was funded by Astellas Pharma Inc. Amit Bahl has received honoraria from Johnson & Johnson, Astellas, Bayer, ACCORD, and AAA Pharmaceutical, and has received research grants from and has participated in advisory boards for Janssen and Bayer. Andrew Chilelli, Rita Faria, Nigel Rozario, Robert Snijder, and Sari Stark are employees of Astellas Pharma Europe Ltd. Axel Merseburger has received honoraria from Janssen, Astellas, Novartis, Telix, Amgen, Ipsen, Takeda, Recordati, and Bayer. Support for medical writing and editing was provided by Olga Klibanov (PharmD) and Daria Renshaw (BA) via IQVIA, funded by the study sponsors.

Träger	Trägernummer
Astellas Pharma Inc.
Janssen Pharmaceutical Companies of Johnson & Johnson
Daria Renshaw
Astellas Pharma
ACCORD
AAA Pharmaceutical
Bayer

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

DFG-Fachsystematik

2.22-23 Reproduktionsmedizin, Urologie

Dokumente

10.1007/s00345-025-06100-7

Weitere Links

Zitieren

Bahl, A., Chilelli, A., Faria, R., Rozario, N., Snijder, R., Stark, S., & Merseburger, A. S. (2026). Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. World Journal of Urology, 44(1), Artikel 5. https://doi.org/10.1007/s00345-025-06100-7

Bahl, Amit ; Chilelli, Andrew ; Faria, Rita et al. / Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re : Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. in: World Journal of Urology. 2026 ; Jahrgang 44, Nr. 1.

@article{7163385bf1e74bd3be16ea1187d78da8,

title = "Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar{\textquoteright}s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9",

author = "Amit Bahl and Andrew Chilelli and Rita Faria and Nigel Rozario and Robert Snijder and Sari Stark and Merseburger, \{Axel S.\}",

year = "2026",

month = jan,

doi = "10.1007/s00345-025-06100-7",

language = "English",

volume = "44",

journal = "World Journal of Urology",

issn = "0724-4983",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

Bahl, A, Chilelli, A, Faria, R, Rozario, N, Snijder, R, Stark, S & Merseburger, AS 2026, 'Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9', World Journal of Urology, Jg. 44, Nr. 1, 5. https://doi.org/10.1007/s00345-025-06100-7

Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. / Bahl, Amit; Chilelli, Andrew; Faria, Rita et al.
in: World Journal of Urology, Jahrgang 44, Nr. 1, 5, 01.2026.

Publikation: Beiträge in Fachzeitschriften › Briefe › Begutachtung

TY - JOUR

T1 - Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re

T2 - Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9

AU - Bahl, Amit

AU - Chilelli, Andrew

AU - Faria, Rita

AU - Rozario, Nigel

AU - Snijder, Robert

AU - Stark, Sari

AU - Merseburger, Axel S.

PY - 2026/1

Y1 - 2026/1

UR - https://www.scopus.com/pages/publications/105023232274

UR - https://www.mendeley.com/catalogue/122d42e7-211c-375f-8b30-bec14b243ef7/

U2 - 10.1007/s00345-025-06100-7

DO - 10.1007/s00345-025-06100-7

M3 - Letters

C2 - 41307573

AN - SCOPUS:105023232274

SN - 0724-4983

VL - 44

JO - World Journal of Urology

JF - World Journal of Urology

IS - 1

M1 - 5

ER -

Bahl A, Chilelli A, Faria R, Rozario N, Snijder R, Stark S et al. Reply to Parth Aphale, Shashank Dokania, Himanshu Shekhar’s Letter to the Editor re: Bahl A, Chilelli A, Faria R, et al. Association between major cardiovascular events and abiraterone acetate compared to enzalutamide in patients with metastatic castration-resistant prostate cancer: a post hoc analysis of the EVADE study. World J Urol 43:465. https://doi.org/10.1007/s00345-025-05841-9. World Journal of Urology. 2026 Jan;44(1):5. doi: 10.1007/s00345-025-06100-7